Filing Analysis
iSpecimen Inc. implemented a 1-for-40 reverse stock split effective April 27, 2026, to regain compliance with Nasdaq's minimum bid price requirement. Additionally, the company ratified a 'defective corporate act' by filing a Certificate of Validation for a previous 1-for-20 reverse split from 2024 that was never properly filed with the State of Delaware.
Red Flags
- Large 1-for-40 reverse split ratio suggests significant share price erosion.
- History of non-compliance with Nasdaq minimum bid price requirements.
- Admission of a 'defective corporate act' regarding a previous 1-for-20 reverse split that was not legally finalized in 2024.
- Successive reverse splits (1:20 in 2024 and 1:40 in 2026) indicate chronic value destruction for long-term shareholders.
Key Facts
- Effected a 1-for-40 reverse stock split on April 27, 2026.
- Common stock shares outstanding decreased from 52,639,796 to approximately 1,316,032.
- The split was intended to regain compliance with Nasdaq's minimum bid price requirement.
- Ratified a prior 1-for-20 reverse stock split from September 13, 2024, which was previously unfiled and deemed a 'defective corporate act'.
- Filed a Fifth Amended and Restated Certificate of Incorporation and a Certificate of Validation on April 29, 2026.
iSpecimen Inc. has failed to achieve a quorum for its 2025 Annual Meeting of Stockholders for the fifth consecutive time. The meeting, originally scheduled for December 31, 2025, has been adjourned multiple times and is now rescheduled for May 8, 2026.
Red Flags
- Persistent failure to achieve a quorum (5 consecutive failed attempts).
- Significant delay in corporate governance, with the annual meeting now delayed by over four months.
- Potential shareholder apathy or difficulty in reaching the required voting threshold for micro-cap governance.
Key Facts
- The 2025 Annual Meeting was originally convened on December 31, 2025.
- Quorum was not present at the original meeting or the reconvened meetings on January 23, February 13, March 13, and April 10, 2026.
- The meeting has been adjourned to May 8, 2026, at 9:00 a.m. Eastern Time.
- The record date for stockholders entitled to vote remains November 3, 2025.
- The proposals to be voted on remain unchanged from the definitive proxy statement filed on November 21, 2025.
iSpecimen Inc. announced a significant operational milestone, achieving an 85% reduction in shipping times for human biospecimens. This update was disclosed via a press release on April 9, 2026, and filed under Regulation FD.
Key Facts
- The company issued a press release titled 'iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time' on April 9, 2026.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The report was signed by CEO Katharyn Field on April 10, 2026.
iSpecimen Inc. has adjourned its 2025 Annual Meeting of Stockholders for the fourth consecutive time due to a lack of quorum. The meeting, originally scheduled for December 31, 2025, has been pushed to April 10, 2026.
Red Flags
- Repeated failure (4 times) to achieve a quorum for a mandatory annual meeting.
- Potential risk of non-compliance with Nasdaq Listing Rule 5620(a), which requires companies to hold an annual meeting of shareholders within one year of the end of the fiscal year.
- High level of shareholder apathy or difficulty in soliciting votes, which may hinder the company's ability to pass critical corporate actions.
Key Facts
- The 2025 Annual Meeting was originally convened on December 31, 2025.
- The meeting has been adjourned and reconvened on January 23, 2026, February 13, 2026, and March 13, 2026, failing to reach a quorum each time.
- The next reconvened meeting is scheduled for April 10, 2026, at 9:00 a.m. Eastern Time.
- The record date for stockholders remains November 3, 2025.
- No changes have been made to the proposals described in the Proxy Statement filed November 21, 2025.
iSpecimen Inc. announced the immediate resignation of independent director Siyun Yang on February 17, 2026. Ms. Yang's departure was not due to any disagreements with the company's operations, policies, or practices.
Red Flags
- The resignation creates a vacancy on the Audit Committee, which may require a timely replacement to maintain Nasdaq compliance.
- Relatively short tenure of approximately one year for the departing director.
Key Facts
- Ms. Siyun Yang resigned as a director effective February 17, 2026.
- Ms. Yang had served as an independent director since February 2025.
- She was a member of the Audit Committee and the Nominating and Corporate Governance Committee.
- The company stated there were no disagreements regarding operations, policies, or practices.